Ngam Advisors L.P. Has $8,283,000 Stake in Catalent Inc (CTLT)
Ngam Advisors L.P. increased its position in Catalent Inc (NASDAQ:CTLT) by 2.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 320,561 shares of the company’s stock after buying an additional 6,734 shares during the period. Ngam Advisors L.P. owned approximately 0.26% of Catalent worth $8,283,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. FMR LLC boosted its stake in Catalent by 89.1% in the second quarter. FMR LLC now owns 14,597,087 shares of the company’s stock worth $335,587,000 after buying an additional 6,877,549 shares during the last quarter. Vanguard Group Inc. boosted its stake in Catalent by 15.2% in the second quarter. Vanguard Group Inc. now owns 7,881,737 shares of the company’s stock worth $181,201,000 after buying an additional 1,039,117 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Catalent by 15.5% in the second quarter. BlackRock Fund Advisors now owns 5,721,096 shares of the company’s stock worth $131,528,000 after buying an additional 767,019 shares during the last quarter. Janus Capital Management LLC boosted its stake in Catalent by 1.5% in the second quarter. Janus Capital Management LLC now owns 5,061,371 shares of the company’s stock worth $116,361,000 after buying an additional 73,233 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in Catalent by 23.2% in the second quarter. UBS Asset Management Americas Inc. now owns 4,252,650 shares of the company’s stock worth $97,768,000 after buying an additional 799,498 shares during the last quarter.
Catalent Inc (NASDAQ:CTLT) traded down 0.37% during trading on Wednesday, hitting $24.02. The company’s stock had a trading volume of 330,666 shares. The company has a 50-day moving average of $24.20 and a 200 day moving average of $24.73. Catalent Inc has a one year low of $18.92 and a one year high of $32.24. The firm has a market cap of $3.00 billion and a PE ratio of 28.77.
Catalent (NASDAQ:CTLT) last issued its earnings results on Monday, November 7th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.01. The firm had revenue of $442.20 million for the quarter, compared to analyst estimates of $430.26 million. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.18 EPS. On average, equities analysts forecast that Catalent Inc will post $1.39 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of United States and international copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2016/11/30/ngam-advisors-l-p-has-8283000-stake-in-catalent-inc-ctlt.html.
CTLT has been the subject of a number of recent analyst reports. Jefferies Group reissued a “hold” rating on shares of Catalent in a research report on Thursday, August 4th. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research note on Friday, November 11th. Morgan Stanley restated a “hold” rating on shares of Catalent in a research note on Tuesday, August 30th. TheStreet upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Wednesday, August 17th. Finally, KeyCorp assumed coverage on Catalent in a research note on Wednesday, October 19th. They issued an “overweight” rating and a $29.00 target price for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Catalent currently has a consensus rating of “Hold” and a consensus price target of $28.67.
In related news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the business’s stock in a transaction on Friday, September 9th. The shares were sold at an average price of $23.58, for a total transaction of $403,234,623.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related stocks with our FREE daily email newsletter.